234 related articles for article (PubMed ID: 15563741)
1. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain.
Galer BS; Gammaitoni AR; Oleka N; Jensen MP; Argoff CE
Curr Med Res Opin; 2004; 20 Suppl 2():S5-12. PubMed ID: 15563741
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale.
Argoff CE; Galer BS; Jensen MP; Oleka N; Gammaitoni AR
Curr Med Res Opin; 2004; 20 Suppl 2():S21-8. PubMed ID: 15563743
[TBL] [Abstract][Full Text] [Related]
3. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale.
Gammaitoni AR; Galer BS; Onawola R; Jensen MP; Argoff CE
Curr Med Res Opin; 2004; 20 Suppl 2():S13-9. PubMed ID: 15563742
[TBL] [Abstract][Full Text] [Related]
4. Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study.
Nalamachu S; Crockett RS; Mathur D
J Fam Pract; 2006 Mar; 55(3):209-14. PubMed ID: 16510054
[TBL] [Abstract][Full Text] [Related]
5. Conclusions: chronic pain studies of lidocaine patch 5% using the Neuropathic Pain Scale.
Argoff CE
Curr Med Res Opin; 2004; 20 Suppl 2():S29-31. PubMed ID: 15563744
[TBL] [Abstract][Full Text] [Related]
6. Lidocaine 5% patch: an open-label naturalistic chronic pain treatment trial and prediction of response.
Fishbain DA; Lewis JE; Cole B; Cutler B; Rosomoff HL; Rosomoff RS
Pain Med; 2006; 7(2):135-42. PubMed ID: 16634726
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
[TBL] [Abstract][Full Text] [Related]
8. Introduction: chronic pain studies of the lidocaine patch 5% using the Neuropathic Pain Scale.
Jensen MP
Curr Med Res Opin; 2004; 20 Suppl 2():S1-4. PubMed ID: 15563740
[TBL] [Abstract][Full Text] [Related]
9. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
10. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study.
Gimbel J; Linn R; Hale M; Nicholson B
Am J Ther; 2005; 12(4):311-9. PubMed ID: 16041194
[TBL] [Abstract][Full Text] [Related]
11. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis.
Galer BS; Sheldon E; Patel N; Codding C; Burch F; Gammaitoni AR
Curr Med Res Opin; 2004 Sep; 20(9):1455-8. PubMed ID: 15383194
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale.
Jensen MP; Dworkin RH; Gammaitoni AR; Olaleye DO; Oleka N; Galer BS
J Pain; 2005 Feb; 6(2):98-106. PubMed ID: 15694876
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy.
Herrmann DN; Barbano RL; Hart-Gouleau S; Pennella-Vaughan J; Dworkin RH
Pain Med; 2005; 6(5):379-84. PubMed ID: 16266359
[TBL] [Abstract][Full Text] [Related]
14. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial.
Katz NP; Gammaitoni AR; Davis MW; Dworkin RH;
Pain Med; 2002 Dec; 3(4):324-32. PubMed ID: 15099237
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds.
Affaitati G; Fabrizio A; Savini A; Lerza R; Tafuri E; Costantini R; Lapenna D; Giamberardino MA
Clin Ther; 2009 Apr; 31(4):705-20. PubMed ID: 19446144
[TBL] [Abstract][Full Text] [Related]
16. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid injection treatment to the ischiadic spine reduced pain in women with long-lasting sacral low back pain with onset during pregnancy: a randomized, double blind, controlled trial.
Torstensson T; Lindgren A; Kristiansson P
Spine (Phila Pa 1976); 2009 Oct; 34(21):2254-8. PubMed ID: 19934804
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
Barbano RL; Herrmann DN; Hart-Gouleau S; Pennella-Vaughan J; Lodewick PA; Dworkin RH
Arch Neurol; 2004 Jun; 61(6):914-8. PubMed ID: 15210530
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study.
Perrot S; Krause D; Crozes P; Naïm C;
Clin Ther; 2006 Oct; 28(10):1592-606. PubMed ID: 17157115
[TBL] [Abstract][Full Text] [Related]
20. Topical lidocaine patch therapy for myofascial pain.
Dalpiaz AS; Lordon SP; Lipman AG
J Pain Palliat Care Pharmacother; 2004; 18(3):15-34. PubMed ID: 15364629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
